Диссертация (1335885), страница 33
Текст из файла (страница 33)
– 1990. – 5. – p.242 – 249.127.Carrasco J.L., Sandner C. Clinical effects of pharmacologicalvariations in selective serotonin reuptake inhibitors: an overview.//International J.Clin. Practice. 2005. - Vol. 59, № 12. - p. 1428-1434.128.Cowen P.J. Pharmacological management of treatment-resistantdepression.// Advance in psychiatric Triatment.-1998.-4.-p.320-327.129.Cruz N., Sanchez – Moreno J., Torrest F., Goikolea J.M., Valenti M.,Vieta E. Efficacy of modern antipsychotics in placebo – controlled trials inbipolar depression: a meta – analysis.// Jnt.
J. Neuropsychopharmacol. – 2010. –13(1). – p.5-14.130.Cutler A.J., Montgomery S.A., Feifel D., Laazarus A., Aström M.,Brecher M. Extended release quetiapine fumarate monotherapy in majordepressive disorder: a placebo – and duloxetine controlled study.//J. Clin.Psychiatry. – 2009. – 70(4). - p. 526-539.131.De Battista C., Hawkins J. Utility of atypical antipsychotics in thetreatment of resistant unipolar depression.//CNS Drugs. – 2009. – 23(5).
– p. 369377175132.De Yong J., Hoogenboom B., van Troostwijk L.D., de Haan L.Interaction of olanzapine with fluvoxamine. //Psychopharmacology (Berl.). –2001. – May. 155 (2). – p. 219 – 220.133.Del Zompo M., Bocchetta A., Bernardi F. et al. Clinical evidence fora role of dopaminergic system in depressive syndromes. //Jn. Dopamine andmental depression. G.L.Gessa, G.Serra (tds.). Oxford6 Pergamon Press.
– 1990. –p. 177 – 184.134.Dhir A., Kulkarni S.K. Risperidone, an atypical antipsychoticenhances the antidepressant-like effect venlafaxine or fluoxetine: Possibleinvolvement of alfa-2 adrenergic receptors.//Neuroscience Letters.-2008.-445.p83-88.135.Dodd S., Berk M. Olanzapine / fluoxetine combination for treatmentresistant depression: efficacy and clinical utility.//Expert.
Rev. Neurother. – 2008.– 8(9). – p.1299-1306.136.Dunner D.L., Amsterdam J.D., Shelton R.C. et al. Efficacy andtolerability of adjunctive ziprasidone in treatment-resistant depression: Arandomized, open-label, pilot study.//Journal of Clinical Psychiatry. – 2007. –68(7). – p.137.Dufour A., Desanti C. Pharmacokinetics and metabolism ofamisulpride.
//Ann. Psychiat. – 1998. – 3. – 3. –p. 298 – 305.138.Eckert A. Clinically relevant drug interactions with new generationantidepressants and antipsychotics.// Ther. Umsch. – 2009. – 66(6). – p. 485–492.139.Ershefsky L., Riesenman C., Lam Y.W.F. Antidepressant druginteraction and the cytochrome P450 system. The role cytochrome P450 2D6.//Clin.Pharmacokinet. - 1995. - vol. 29 (suppl.1). – p.10-19.140.Euglisch S., Fritzinger M., Zink M. Urinary retention duringcombined treatment of postpsychotic depression with duloxetine and olanzapine.// Clin. Neuropharmacol.
– 2008. – 31(5). – p. 307-309.176141.Fava G.A., Fabbri S., Sonino N. Residual symptoms in depression:An emerging therapeutic target Progress in Neuro-Psychopharm. AndBiolog.Psychiatry.-2002.-26.-p.1019-1027.142.Fava G.A., Ruini Ch., Belaise C. The concept of recovery in majordepression.//Psychological Medicine.-2007.-37.-p.15-19.143.Fava M., Davidson K.G. Definition and epidemiology of treatment –resistant depression.// Psychiatr. Clin.
Noth. Am. – 1996. – 19. – p. 179 – 200.144.Ferrari A.I., Charlson F.I., Norman R.E., Flaxman A.D.,Patten S.B.,Vos T., application for the global Burden of Disease study 2010.//Plos One2013.-23.-8.-7.-69637145.Fazzari G., Benzoni O., Sangaletti A., Bonera F., Nassini S.,Mazzarini L., Pacchiarotti I., Sani G., Kaukopoulos A.E., Sanna L., Gasparotti R.,De Rossi P., Lazanio S., Savoja V., Girardi P. Improvement of cognition in apatientwithCotard'sdelusionsandfrontotemporalatrophy receivingelectroconvulsive therapy (ECT) for depression.//Jnt.
Psychogeriatr. - 2009. 21(3). – p. 600-603.146.FDA. Electronic Orange Book Apporoved Drug Products withTherapeutic Equivalence Evaluations, 20thEdition.2000 The rules govemingmedical products in the Europe no?147.Fischer M.f., Avorn J. Potential saving from increased use of genericexperience of Medicaid and other insurance programs means for a Medicare drugbenefit.// Pharmacoepidemiol. Drug Saf.-2004.-Apr.-13(4).-p.207-214.148.Freedman R. Drug therapy: schizophrenia.// N. Engl. J.Med.-2003.-348.-p. 1738-1749.149.Freemantle N., Anderson I.M., Yang P.
Predictive value ofpharmacological activity for the relative efficacy of antidepressant drugs. Meta –regression analysis.//Br. J. Psychiatry. – 2000. – 177. – p. 292 – 302.150.Gao К., Cajwani P, Elhaj O., Calabrese J.R. Typical and atypicalantipsychotics in bipolar depression.// J. Clin. Psychiatry. -2005 – Nov. – 66 (11).– p. 1376 – 1385.177151.Gillet G., Dormerque M., Canal M. et al. Amisulpride does notinhibit cytochrome P 450 isozymes.// Eur. Neuropsychopharmacol.
– 2000. – 10/- supp. 3. – p.331.152.Global comparation pharmaceutical expeditures with relatedreference information.WHO,2000(EDM/p/2000-2)153.Goshen I., Kreisel T., Ounallah-Saad H., Renbaum P., Zalzstein V.,Ben-Hur T. et al. A.dual role for interleukin-1 in hippocampal- dependentmemory process.//Psychoneuroendocrinology.-2007.-32.-1106-1115.154.Gossen D., de Suray J. M., Vandenhende F., Onkelinx C., Gandji D.Influence of fluoxetine on olansapine pharmacokinetics.//AAPS Pharm. Sci. –2002. - 4(2).
–p. 11.155.Green B. Focus on amisulpride.//Curr.Med.Res.Opin. – 2002. –18(3). – p. 113 – 117.156.Grigorieva E., Dyakonov A. Comparative evalution of efficacyprozac and combination prozac and zyprexa at treatment of depressive disorders.// 13 World Congress of psychiatry Cairo, sept. 10 – 15. – 2005. – p.717157.Gureje O., Maj M. et al. Образовательная программа подепрессивным расстройствам (редакция 2008 г.) ВОЗ. Перевод подредакцией В.Н.Краснова.//М.-2010.-119 с.158.Guberman A., Gorman C. Generic substitution for brand nameantiepileptic drugs: a survey// Can.J.Neurol. – Sci. 2000.-Feb.-27(1).-p.37-43159.Hirose S., Ashby C.R.
An open pilot study combining risperidoneand a selective serotonin reuptake inhibitor as initial antidepressant therapy. //J.Clin. Psychiatry. - 2002. – Aug. 63 (8). – p. 733-736.160.Hüther R., Gebhart C., Mirisch S., Bäuml J., Förstl H. Choreaticsymptoms during and after treatment with paleperidone and escitalopram.//Pharmacopsychiatry. – 2008. – 41(5). – 203-204.161.Isbister G.K., Dawson A.H., Whyte J.M. Comment: neurolepticmalignant syndrome associated with risperidone and fluvoxamine.//AnnPharmacother. - 2002. – Jul. 36 (7).
- p. 1294.178162.Israel J.A. Remission in depression: definition and initial treatmentapproaches.//Psychopharmacol.-2006.-20.-p.5-10.163.Jerling M. Lindstrom L., Bondesson U., Berlisson L. Fluvoxamineinhibition and carbamazepine induction of the metabolism of clozapine: evidencefrom a therapeutic drug monitoring servis.//Ther.Drug.Monit. – 1994. – v.16. – p.368 – 374.164.Johnston A., Stayles P., Stergion G. Effectiveness, safety and costof drug substitution in hypertension.//Br. J.Clin.Pharmacol.-2007. - 3.-p.320 334.165.Kasper S.
Treatment of depressive symptomswith quentiapine.//Expert Review of Neurotherapeutics, - 2003. – 3(4). – p. 417 – 423.166.Kauer – Sant A.M., Kapczinski F., Vieta E. Epidemiology andmanagement of anxiety in patients with bipolar disorder.//CNS Drugs. – 2009. –1. – 23(11). – p. 953 – 964.167.Keitner G.I., Garlow S.J., Rian C.E. A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treatunipolar, non-psychotic major depression.//Journal of Psychiatric Research.2009.-43.-p.205-214.168.Keller M.B., Lavori P.W., Mueller T.I. et al.
Time to recovery,chronicity and levels of psychopatology in major depression. A 5-yearprospective follow-up of 431 subjects.//Arch. Gen Psychiatry.-1992.-49.-p.809816.169.Keller M.B.,.Shapiro R.W, Lavori P.W., Wolfe N. Relapse in majordepressive disorder: analisis with the life table.//Arch.
Gen Psychiatry.-1982.-39.p.911-915.170.KennedyS.H.Fullremission:areturntonormalfunctioning.//J.Psychiatry Neurosci.-2002.-27.-4.-p.233-234.171.Kennedy S.H. Shortcoming of current antidepressant therapies.//Medicographia. – 2005. -3. –p. 240 – 246.179172.KennedyS.H.,EisfeldB.C.,MayerJ.H.,BagbyR.M.Antidepressants in clinical practice: limitations of assessment methods and groupresponse. // Hum. Psychopharmacol.
– 2001. – 16. – 105 – 114.173.Kessing L.V., Andersen P.K. Evidence for clinical progression ofunipolar and bipolar disorders.// Acta.psychiatr. Scand.-2017.-135.-p.51-64.174.KnopfU.,Hubrich-Ungureamiaugmentation with risperidone in therapy -P.,ThomeJ.Paroxetineresistant depression . Original:[Paroxetin – augmentation mit risperidone bei therapie resistenter Depression.]// Psychiatr. Prax. - 2001.
– Nov. 28 (8). – p. 405-406.175.Konig F., von Hippel C., Petersdorff T., Neuhoffer –Weiss M.,Wolfersdorf M., Kachka W.P. First experiences in combination therapy usingolansapine with SSRIs (citalopram, paroxetine) in delusional depression.//Neuropsychobiology. - 2001. - 43 (3). – p. 170-174.176.Kristoffersen J., Sorensen C.H., Nielsen C.T., Stage K.B. Treatmentof psychotic depression.//Ugeskr. Zaeger. – 2008. – 10. – 170(46).
– p.37533755.177.Kumar R., Sachdev P.S. Akathisia and second – generationantipsychotic drugs.//Curr. Opin. Psychiatry. – 2009. – 22(30. – p. 293 – 299.178.Lee A.S. Better outcomes for depressive disorders?//Psychol. Med.-2003.-33.-p.163-174.179.Lambert MT, Trutia C, Petty F. Extrapyramidal adverse effectsassociated with sertraline. Prog Neuropsychopharmacol Biol Psychiatry. 1998Jul;22(5):741-8.180.Lecrubier V., Boyer P., Turjanski S., Rein W. Amisulpride versusimipramine and placebo in dysthymia and major depression.//J. Affect. Dis. –1997. – 43.
– p. 95 – 103.181.LemkeM.R. Antidepressanteffects of dopamine agonists.Experimental and clinical findings.//Der Nervenarzt.-2007.- 78 (1).-p. 31-8180182.Leon C.A., Vigoya J., Conde S. et al. Cjmparison of the effect ofamisulpride and viloxazine in the treatment of dysthymia. //Acta Psiguiat Psicol.Am lat. – 1994. – 40. – p. 41 – 49.183.Lepine J.P., Goger J., Blashko C. А double-blind study of theefficacy and safety of sertraline and clomipramine in outpatients with severemajor depression.//Int Clin Psychopharmacol. - 2000. – 12. – p.19 – 30.184.Lexchin J.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
